A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-15. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
=== nanoDSF === nano-Differential scanning fluorimetry, or nanoDSF, is a biophysical characterization technique used for assessing the conformational stability of a biological sample, typically a protein. Samples are subjected to either temperature ramps or gradients of chemical denaturant, and the intrinsic fluorescence is measured and fit to determine the melting point (Tm). Applications include formulation ranking, protein engineering (comparing mutants to wild type), and ligand binding (quantification of affinity constants). A prerequisite of the technique is that the protein must contain an intrinsically fluorescent residue, typically tryptophan or tyrosine residues. Benefits include tag-free analysis, avoidance of extrinsic fluorophores, low sample consumption, easy of use, amenity to automation, and high screening throughput. Drawbacks include a propensity for false positives and negatives, usually necessitating follow-up screening with a potentially lower-throughout orthogonal technique to confirm. Current commercial instruments employ either proprietary capillaries or generic high-throughput 384-well plates for sample analysis.
The stream of protonated water clusters acts as a secondary ionizing species and generates analytes ions by chemical ionization mechanisms at atmospheric pressure. Here protonation, deprotonation, direct charge transfer and adduct ion formation may occur.
Partial history indicators: These are time-temperature indicators that provide a visual indication of whether a product has been exposed to temperatures outside the recommended range during a specific portion of its life cycle. The critical temperature indicator is an example of PHI. This kind of indicator only reacts after a certain temperature is reached, usually picked to match the threshold that, if exceeded, may cause irreversible damage to the product. Full history indicators slowly change color, with its rate varying with the environment temperature (ideally in a way that matches the degradation behavior of the product it's protecting). FHIs are recommended over PHIs in monitoring seafood, because Clostridium botulinum grows at any temperature beyond 38 °F (3 °C), speeding up as it gets warmer. FHIs would be very hard to store and transport if they were already active before meeting the product. As a result, FHIs are sometimes shipped in an inactive configuration with some way to activate them only when needed.
Blue cheese is any cheese made with the addition of cultures of edible molds, which create blue-green spots or veins through the cheese. Blue cheeses vary in flavor from mild to strong and from slightly sweet to salty or sharp; in color from pale to dark; and in consistency from liquid to hard. They may have a distinctive smell, either from the mold or from various specially cultivated bacteria such as Brevibacterium linens. Some blue cheeses are injected with spores before the curds form, and others have spores mixed in with the curds after they form. Blue cheeses are typically aged in temperature-controlled environments.
Sources: en.wikipedia.org
=== Prostitution === Shortly after giving birth to her second child, Rose began to work as a prostitute, operating from an upstairs room at Cromwell Street and advertising her services in a local contact magazine. Fred encouraged Rose to seek clients in Gloucester's West Indian community through these advertisements. In addition to her prostitution, Rose engaged in casual sex with both male and female lodgers within their household, and individuals Fred encountered via his work. She also bragged to several people that no man or woman could completely satisfy her. When engaging in sexual relations with women, Rose would gradually increase the level of brutality to which she subjected her partner, with acts such as partially asphyxiating her partner or inserting increasingly large dildos into her partner's body. If the woman resisted or expressed any pain or fear, Rose would become greatly excited and typically ask: "Aren't you woman enough to take it?" To many of these women, it became apparent Rose and her husband (who regularly participated in threesomes with his wife and her lovers) took a particular pleasure from taking women beyond their sexual limits—typically via sessions involving bondage. The Wests openly admitted to taking a particular pleasure from any form of sex involving a strong measure of dominance, violence and pain. To cater to these fetishes, they amassed a large collection of bondage and restraining devices, magazines and photographs, later expanding this collection to include videos depicting bestiality and graphic child sexual abuse.
==== Storage ==== Eighty to ninety percent of the total body reserves of preformed vitamin A are in the liver (with 80–90% of this amount being stored in hepatic stellate cells and the remaining 10–20% being stored in hepatocytes). Fat is another significant storage site, while the lungs and kidneys may also be capable of storage.
In August 1967, brothers Michael and Peter Giles, drummer and singer/bassist respectively, and professional musicians in working bands since their mid-teens in Dorset, England, advertised for a "singing organist" to join a new group they were forming. Fellow Dorset musician Robert Fripp – a guitarist who neither sang or played organ – responded, and Giles, Giles and Fripp was born. The trio signed to Deram Records and recorded one album, The Cheerful Insanity of Giles, Giles and Fripp, released in 1968. They hovered on the edge of success, but were never able to make a commercial breakthrough. Attempting to expand their sound, the three recruited Ian McDonald on keyboards and woodwinds. McDonald brought along two other participants: his then-girlfriend, former Fairport Convention singer Judy Dyble, whose brief tenure with the group ended when the two split, and lyricist, roadie, and art strategist Peter Sinfield, with whom he had been writing songs – a partnership initiated when McDonald had said to Sinfield (regarding his band Creation), "Peter, I have to tell you that your band is hopeless, but you write some great words. Would you like to get together on a couple of songs?" Fripp, meanwhile, saw Clouds at the Marquee Club in London, which spurred him to incorporate classical-inspired melodies into his writing and utilise improvisation to find new ideas. No longer interested in Peter Giles's more whimsical pop songs, Fripp recommended that his old friend, fellow guitarist and singer Greg Lake, could join to replace either Peter or Fripp himself.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.